Mosunetuzumab, a Full-Length Bispecific CD20/CD3 Antibody, Displays Clinical Activity in Relapsed/Refractory B-Cell Non-Hodgkin Lymphoma (NHL): Interim Safety and Efficacy Results from a Phase 1 Study

被引：42

作者：

Budde, Lihua E. ^{[1
]}

Sehn, Laurie H. ^{[2
,3
]}

Assouline, Sarit ^{[4
]}

Flinn, Ian W. ^{[5
]}

Isufi, Iris ^{[6
]}

Yoon, Sung-Soo ^{[7
]}

Kim, Won-Seog ^{[8
]}

Matasar, Matthew J. ^{[9
]}

Nastoupil, Loretta J. ^{[10
]}

Santiago, Raoul ^{[4
]}

Koh, Youngil ^{[7
]}

Hernandez, Genevive ^{[11
]}

Li, Chi-Chung ^{[11
]}

Kulkarni, Priya R. ^{[11
]}

McCall, Bruce ^{[11
]}

McClellan, Scott ^{[11
]}

Yin, Shen ^{[11
]}

Gupta, Vinita ^{[11
]}

Chu, Yu-Waye ^{[11
]}

Bartlett, Nancy L. ^{[12
]}

机构：

[1] City Hope Natl Med Ctr, Duarte, CA USA

[2] BC Canc Ctr Lymphoid Canc, Vancouver, BC, Canada

[3] Univ British Columbia, Vancouver, BC, Canada

[4] Jewish Gen Hosp, Montreal, PQ, Canada

[5] Tennesse Oncol, Sarah Cannon Res Inst, Nashville, TN USA

[6] Yale Univ, New Haven, CT USA

[7] Seoul Natl Univ Hosp, Seoul, South Korea

[8] Samsung Med Ctr, Seoul, South Korea

[9] Mem Sloan Kettering, New York, NY USA

[10] Univ Texas MD Anderson Canc Ctr, Houston, TX 77030 USA

[11] Genentech Inc, San Francisco, CA 94080 USA

[12] Washington Univ, Sch Med, Siteman Canc Ctr, St Louis, MO USA

来源：

关键词：

D O I：

10.1182/blood-2018-99-118344

中图分类号：

R5 [内科学];

学科分类号：

1002 ; 100201 ;

摘要：

399

引用

页数：4